Selected Protocols for the Treatment of
Hematologic Malignancies in Adults
Applicable Disease(s)/Treatment(s)
Study Name
Principal Investigator
LEUKEMIA
Acute T-cell Lymphoblastic Leukemia
•Relapsed/Refractory
T-cell Lymphoblastic Lymphoma
•Relapsed/Refractory
Study to evaluate the safety and tolerability of weekly intravenous
doses of BMS-906024 in patients with acute T-cell lymphoblastic
leukemia or T-cell lymphoblastic lymphoma
Protocol # 11-290
Daniel DeAngelo, MD, PhD
617-632-2645
daniel_deangelo@dfci.harvard.edu
LEUKEMIA
Myelodysplastic Syndromes
Phase I/II pharmacokinetic guided dose-escalation and doseconfirmation study of ASTX727, a combination of the oral cytidine
deaminase inhibitor (CDAi) E7727 with oral decitabine in patients
with myelodysplastic syndromes (MDS)
Protocol # 14-195
David Steensma, MD
617-632-5202
david_steensma@dfci.harvard.edu
LEUKEMIA
Myeloproliferative Disorders
Myelofibrosis
Phase I/II open-label, dose-escalation, multi-center study to assess
the safety, tolerability, pharmacokinetics, and pharmacodynamics of
orally administered NS-018 in patients with primary myelofibrosis,
post-polycythemia vera myelofibrosis, or postessential thrombocythemia myelofibrosis
Protocol # 13-109
Martha Wadleigh, MD
617-632-3712
martha_wadleigh@dfci.harvard.edu
LEUKEMIA
Chronic Myelogenous Leukemia
Acute Lymphoblastic Leukemia
Phase I, multi-center, open-label study of oral ABL001 in patients
with chronic myelogenous leukemia or Philadelphia Chromosomepositive acute lymphoblastic leukemia
Protocol # 14-117
Daniel DeAngelo, MD, PhD
617-632-2645
daniel_deangelo@dfci.harvard.edu
LEUKEMIA
Acute Myeloid Leukemia
Myelodysplastic Syndromes
Phase I, multi-center, open-Label, dose-escalation, safety,
pharmacokinetic, pharmacodynamic, and clinical activity study of
orally- administered AG-120 in patients with advanced hematologic
malignancies with an IDH1 mutation
Protocol # 12-288
Richard Stone, MD
617-632-1906
richard_stone@dfci.harvard.edu
LEUKEMIA
Hairy Cell Leukemia
Phase II study of BRAF inhibitor, Vemurafenib, in patients with
relapsed or refractory hairy cell leukemia
Protocol # 13-352
Richard Stone, MD
617-632-1906
richard_stone@dfci.harvard.edu
LYMPHOMA
Hodgkin Lymphoma
Phase 2 Study of Nivolumab (anti-PD1 antibody) in Hodgkin
Lymphoma
Protocol #14-242
Philippe Armand, MD, PhD
617-632-2305
philippe_armand@dfci.harvard.edu
LYMPHOMA
Diffuse Large B-Cell Lymphoma
Phase 2 Study of Nivolumab (Anti-PD1 Antibody) in Diffuse
Large B-Cell Lymphoma
Protocol #14-157
Philippe Armand, MD, PhD
617-632-2305
philippe_armand@dfci.harvard.edu
LYMPHOMA
Follicular Lymphoma
Phase 2 Study of Nivolumab (Anti-PD1 Antibody) in
Follicular Lymphoma
Protocol #14-159
Philippe Armand, MD, PhD
617-632-2305
philippe_armand@dfci.harvard.edu
Winter 2014
www.dfbwcc.org/clinicaltrials
Selected Protocols for the Treatment of
Hematologic Malignancies in Adults
Applicable Disease(s)/Treatment(s)
Study Name
Principal Investigator
CHRONIC LYMPHOCYTIC
LEUKEMIA
• No Prior Therapy
Idelalisib-Ofatumumab for Untreated Patients
Protocol #13-309
Jennifer R. Brown, MD, PhD
617-632-4564
jennifer_brown@dfci.harvard.edu
CHRONIC LYMPHOCYTIC
LEUKEMIA
• No Prior Therapy
Ibrutinib-FCR for Untreated Patients
Protocol #14-296
Matthew Davids, MD
617-632-1906
matthew_davids@dfci.harvard.edu
CHRONIC LYMPHOCYTIC
LEUKEMIA
• Relapsed
Ibrutinib-TGR PI3K Inhibitor for Relapsed Patients
Protocol #14-396
Matthew Davids, MD
617-632-6331
matthew_davids@dfci.harvard.edu
CHRONIC LYMPHOCYTIC
LEUKEMIA
LYMPHOMA
Phase 1 Study of Anti-LAG3 Antibody in Lymphoma and CLL
Protocol #14-072
Philippe Armand, MD, PhD
617-632-2305
philippe_armand@dfci.harvard.edu
LYMPHOMA
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
Phase 1 Combination Study of Nivolumab (Anti-PD1 Antibody)
and Ipilimumab (Anti-CTLA4 Antibody) in Hodgkin and
Non-Hodgkin Lymphoma
Protocol #12-317
Philippe Armand, MD, PhD
617-632-2305
philippe_armand@dfci.harvard.edu
MULTIPLE MYELOMA
•Newly Diagnosed
Randomized trial of lenalidomide, bortezomib, dexamethasone
versus high-dose treatment with stem cell transplantation in
multiple myeloma patients up to age 65.
Protocol # 10-106
Paul Richardson, MD
617-632-2104
paul_richardson@dfci.harvard.edu
MULTIPLE MYELOMA
•Relapsed /Refractory
Open-label study of TH-302 and dexamethasone with or without
bortezomib in patients with relapsed/refractory multiple myeloma.
Protocol # 11-425
Irene Ghobrial, MD
617-632-2127
irene_ghobrial@dfci.harvard.edu
MULTIPLE MYELOMA
•Relapsed /Refractory
A Phase I/II Study of Pomalidomide, Dexamethasone and MLN9708
vs. Pomalidomide and Dexamethasone for Patients with Multiple
Myeloma Refractory to Lenalidomide and
Proteasome Inhibitor-Based Therapy.
Protocol# 14-334
Claudia-Paba Prada, MD
617-632-4198
claudiap_prada@dfci.harvard.edu
MULTIPLE MYELOMA
•Relapsed /Refractory
A Phase I, Multicenter, Open-label, Combination Study of
Pomalidomide, Marizomib, and Low-Dose Dexamethasone (PMD)
in patients w/ Relapsed or Refratory Multiple Myeoma.
Protocol# 14-028
Jacob Laubach, MD
617-582-7102
jacob_laubach@dfci.harvard.edu
MULTIPLE MYELOMA
•Relapsed /Refractory
Phase Ib/2, Multi-center, Open Label Study of Oprozomib
and Dexamethasone and/or Refractory Multiple Myeoma.
Protocol# 13-362
Claudia-Paba Prada, MD
617-632-4198
claudiap_prada@dfci.harvard.edu
MULTIPLE MYELOMA
• Relapsed / Refractory
A Phase 3, Multicenter, Randomized, Open-label Study to
Compare the Efficacy and Safety of Pomalidomide (POM),
Bortezomib (BTZ) andLow-Dose Dexamethasone vs. Bortezomib
and Low Dose Dexamethasone in patients with Relapsed or
Refractory Multiple Myeloma.
Protocol # 13-225
Paul Richardson, MD
617-632-2104
paul_richardson@dfci.harvard.edu
MULTIPLE MYELOMA
• Relapsed / Refractory
A phase I open label study of panobinostat in combination with
RVD in patients with Relapsed or Refractory Multiple Myeloma.
Protocol # 13-262
Jacob Laubach, MD
617-582-7102
jacob_laubach@dfci.harvard.edu
Winter 2014
www.dfbwcc.org/clinicaltrials
Selected Protocols for the Treatment of
Hematologic Malignancies in Adults
Applicable Disease(s)/Treatment(s)
Study Name
Principal Investigator
STEM CELL TRANSPLANT
Standard of Care vs. Bortezomib in Graft-Versus-Host-Disease
After Hematopoietic Stem Cell Transplant
Protocol # 12-404
John Koreth, MBBS, DPhil
617-632-2949
john_koreth@dfci.harvard.edu
Ibrutinib-TGR PI3K Inhibitor for Relapsed Patients
Protocol # 14-396
Matthew Davids, MD
617-632-6331
matthew_davids@dfci.harvard.edu
Single ProHema Modulated-Cord Blood Unit as Part of a Double
Cord Blood Transplant in Patients with Hematologic Malignancies
Protocol # 12-321
Corey Cutler, MD, MPH, FRCPC
617-632-5946
corey_cutler@dfci.harvard.edu
Trial of Regulatory T-cells Plus Low-Dose Interleukin-2 for
Steroid-Refractory Chronic Graft-Versus-Host-Disease
Protocol # 13-281
John Koreth, MBBS, DPhil
617-632-2949
john_koreth@dfci.harvard.edu
Phase 1 Study of Abatacept in the Treatment of Patients With
Steroid Refractory Chronic Graft-Versus-Host-Disease
Protocol # 13-358
Robert Soiffer, MD
617-632-6256
robert_soiffer@dfci.harvard.edu
A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory
Acute Graft-versus-Host-Disease
Protocol # 13-593
John Koreth, MBBS, DPhil
617-632-2949
john_koreth@dfci.harvard.edu
Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting
NKG2D-Ligands
Protocol # 14-386
Susanne Baumeister, MD
617-632-4687
susanne_baumeister@dfci.harvard.edu
Ibrutinib With Rituximab in Previously Treated Adults with
Waldenstrom’s Macroglobulinemia
Protocol # 14-250
Steven Treon, MD, PhD
617-632-6844
steven_treon@dfci.harvard.edu
GVHD
STEM CELL TRANSPLANT
CHRONIC LYMPHOCYTIC
LEUKEMIA
• Relapsed
STEM CELL TRANSPLANT
LEUKEMIA
Acute Lymphocytic Leukemia
• Remission
Acute Myelogenous Leukemia
• Remission
Biphenotypic/Undifferentiated
Leukemia
• Remission
LYMPHOMA
Hodgkin Lymphoma
• Remission
Non-Hodgkin Lymphoma
• Remission
STEM CELL TRANSPLANT
GVHD
STEM CELL TRANSPLANT
GVHD
STEM CELL TRANSPLANT
GVHD
CELLULAR THERAPY
LEUKEMIA
Acute Myelogenous Leukemia
MULTIPLE MYELOMA
WALDENSTRÖM’S
MACROGLOBULINEMIA
•Previously Treated
Winter 2014
www.dfbwcc.org/clinicaltrials
Selected Protocols for the Treatment of
Hematologic Malignancies in Adults
The above-listed trials are only a sampling of our many open and accruing studies. If you are interested in, or would like
more information about, a clinical trial listed here, please contact the principal investigator.
For a broader listing of treatment protocols, please visit our website at www.dfbwcc.org/clinicaltrials.
The clinical trials listed above are conducted through Dana-Farber/Harvard Cancer Center, an NCI-designated Comprehensive Cancer Center,
and are available at other member institutions.
*This trial is also available at Massachusetts General Hospital Cancer Center.
Selected Protocols for the Treatment of
Hematologic Malignancies in Adults
www.dfbwcc.org/clinicaltrials
Winter 2014